Generali Investments CEE investicni spolecnost a.s. Acquires 540 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Generali Investments CEE increased its holdings in Regeneron Pharmaceuticals by 33.1%, acquiring an additional 540 shares, bringing total shares to 2,170 valued at approximately $1,139,000.
• Regeneron reported earnings of $12.89 EPS for the last quarter, exceeding estimates by $4.46, with revenues of $3.68 billion, surpassing expectations of $3.30 billion.
• The stock has an average price target of $817.67, with analysts rating it an overall "Moderate Buy".

Generali Investments CEE investicni spolecnost a.s. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 33.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,170 shares of the biopharmaceutical company's stock after purchasing an additional 540 shares during the period. Generali Investments CEE investicni spolecnost a.s.'s holdings in Regeneron Pharmaceuticals were worth $1,139,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of REGN. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after purchasing an additional 686 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 334.6% during the 1st quarter. Versant Capital Management Inc now owns 226 shares of the biopharmaceutical company's stock worth $143,000 after acquiring an additional 174 shares during the period. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 23.5% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,357 shares of the biopharmaceutical company's stock worth $861,000 after acquiring an additional 258 shares during the period. American National Bank & Trust bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $44,000. Finally, NBC Securities Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $78,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ REGN opened at $562.27 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,061.60. The firm has a 50 day moving average price of $570.12 and a two-hundred day moving average price of $568.72. The stock has a market cap of $59.59 billion, a P/E ratio of 14.17, a price-to-earnings-growth ratio of 1.79 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the company posted $11.56 EPS. The company's revenue was up 3.6% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on REGN shares. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target for the company. Morgan Stanley reiterated an "overweight" rating and set a $761.00 price objective (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.